biostudies-literatureUnknown5(9)Hellmann-Regen J<h4>Importance</h4>Insufficient treatment response and resulting chronicity constitute a major problem in depressive disorders. Remission rates range as low as 15% to 40% and treatment-resistant depression (TRD) is associated with low-grade inflammation, suggesting anti-inflammatory interventions as a rational treatment strategy. Minocycline, which inhibits microglial activation, represents a promising repurposing candidate in the treatment of TRD.<h4>Objective</h4>To determine whether 6 weeks of minocycline as add-on to antidepressant treatment as usual can significantly reduce depressive symptoms in patients with TRD.<h4>Design, setting, and participants</h4>The study was conducted in Germany and designed as a multicenter double-blind randomized clinical trial (RCT) of 200 mg/d minocycliJAMA network opene2230367https://www.ebi.ac.uk/biostudies/studies/S-EPMC9475381biostudies-literatureEffect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.PMC9475381Gruber ORupprecht RHeuser IWiltfang JPrvulovic DManook AClemens VBaghai TCPadberg FUhr MHellmann-Regen JHuber CKornhuber JGoya-Maldonado RIsing MReif ASchule CGrozinger MFriede TfalseEffect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.<h4>Importance</h4>Insufficient treatment response and resulting chronicity constitute a major problem in depressive disorders. Remission rates range as low as 15% to 40% and treatment-resistant depression (TRD) is associated with low-grade inflammation, suggesting anti-inflammatory interventions as a rational treatment strategy. Minocycline, which inhibits microglial activation, represents a promising repurposing candidate in the treatment of TRD.<h4>Objective</h4>To determine whether 6 weeks of minocycline as add-on to antidepressant treatment as usual can significantly reduce depressive symptoms in patients with TRD.<h4>Design, setting, and participants</h4>The study was conducted in Germany and designed as a multicenter double-blind randomized clinical trial (RCT) of 200 mg/d minocycli2022-01-01T00:00:00Z2022 Sep2026-06-01T02:24:17.498Z2025-04-04T12:05:15.371ZS-EPMC94753813610318110.1001/jamanetworkopen.2022.30367